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Summary Homozygous nude rats (mu/mu) injected s.c. with 3 x 107 human pancreatic cancer cells from the
GER cell line developed circulating antibody to GER cell surface, detected in a 1251I binding assay against
viable GER cells in vitro. Antibody titre rose with progressive xenograft growth. These antibodies showed no
selectivity for GER cells when compared with a panel of other human cell lines. Heterozygous nude rats
(rnu/+) immunised with serum from their GER xenograft-bearing nude relatives (rnu/mu) also developed
anti-GER cell surface antibodies. These antibodies showed some selectivity for GER and WAD (a second
human pancreatic cancer cell line) when compared with other human cancer cells and lymphocytes. These
findings show that some human pancreatic cancer cell surface components may persist independently in the
circulation of xenograft bearing mu/mu rats despite the presence of antibody excess to other surface
determinants from the same cells. It is suggested that differences in the relative immune competence of
mu/mu and mu/+rats may offer a biological opportunity for enhancing the recognition of weak antigenic
determinants which may have some useful selectivity for different types of human tumour cells.
Cell surface components have been shown to be
released into tissue culture supernatants by human
and animal tumour cells in vitro (Bystryn, 1977;
Koch & Smith, 1978; Sachs et al., 1980). There is
evidence with animal tumours that this process may
also occur in the host during tumour growth in vivo
(Calafat et al., 1976; Dvorak et al., 1981; Warenius
et al., 1981). If this phenomenon is also a feature of
human tumour growth in nude animals it may offer
a biological selection which can be exploited in the
production of monoclonal antibodies with some
selectivity for the cancer cell surface.
Immunocompetent mice immunised with serum
from human tumour-bearing nude (nu/nu) relatives
develop antibodies which have been shown to react
with the surface of human tumour cells cultured in
vitro (Grant & Duke, 1981).
Although circulating levels of alpha-fetoprotein
(xFP) have been estimated in repeated serum
samples during human tumour growth in nude mice
(Hirohashi et al., 1979) the scope of such serial
studies in the mouse is in general limited by the
small blood volume of the animal. The athymic
Rowett nude rat (mu/mu) has been shown to be a
suitable animal for the in vivo maintenance of
human pancreatic and colonic cancers both from
primary surgical explants and from human
pancreatic excorine adenocarcinoma cells (GER) in
culture (Davies et al., 1981). This larger nude
mutant offers some experimental advantages which
may complement the study of human tumours in
nude mice.
The purpose of the present investigation was to
examine the appearance of human pancreatic
cancer cell-surface components in the circulation of
the tumour-bearing nude rats by the antibody
response of immunocompetent hairy littermates
immunised with tumour-bearer sera. In addition we
wished to characterise the antibody response of the
tumour-bearer animal itself, to cell surface
components throughout the period of pancreatic
tumour growth.
Materials and methods
Rats
Three month old congenitally athymic female nude
rats (mu/mu) were obtained from Olac 1976 Ltd.
Hairy littermates (mu/+) were bred in our
laboratory by mating homozygous nude males
(mu/mu) with heterozygous females (rnu/+). All
the rats used in this study were maintained in an
isolated facility; nude animals were protected in
filter boxes and their immunocompetent hairy
littermates were housed in conventional conditions.
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Cell lines andxenografts
Human pancreatic exocrine adenocarcinoma cells240 G. DAVIES et al.
(GER) (Grant et al., 1979) were cultured, harvested
and implanted in 12 nude rats as previously
described (Davies et al., 1981). A second human
pancreatic cancer cell line (WAD), a human kidney
carcinoma cell line (GYL) and a human colon
carcinoma cell line (CAS) all established in vitro in
this laboratory from primary tumour-derived
xenografts growing in nude rats (unpublished data),
were also used. The panel of human carcinoma cell
lines included HL60 (lymphoblastoid), MDA-157
(breast), TCC-Sup and J82 (bladder) and HT29
(colon) as described previously (Grant & Duke,
1981). Normal human peripheral blood
lymphocytes (HLSK) were prepared by Ficollpaque
(Pharmacia) separation.
Serial blood samplingfrom tumour-bearing animals
Of the 12 animals in which 3 x 107 pancreatic
adenocarcinoma cells (GER) were implanted,
tumours grew progressively in 8; all animals were
bled before tumour cell implantation, Day 0, and
subsequently at Day 7, Day 14 and therafter every
21 days for up to 7 months. Each animal was bled
from the tail vein; 1.7ml of blood yielded 0.6ml of
serum per bleed. All bleeds were performed under
general anaesthesia using nitrous oxide, oxygen and
halothane in a Hepaire flow cabinet. CEA-like
immunoreactivity in serum samples was measured
in the Department of Medical Oncology, Charing
Cross Hospital, by radioimmunoassay as described
by Laurence et al. (1972) using heterologous goat
anti-CEA antibody; aFP estimation was performed
by the protein reference library, Putney Hospital,
using an adaptation of the aFP radioimmunoassay
method ofNishi & Hirai (1973).
Immunisation of hairy littermates with serum of
tumour-bearing nude rats
Blood was collected by cardiac puncture from 8
additional human pancreatic tumour-bearing nude
rats derived from a previous study (Davies et al.,
1981) when the tumours were about 4 x 3 cm in
size; serum was separated, pooled, aliquoted and
stored at -20°C until used. Four hairy littermates
(HLM I-HLM IV) received 0.5ml of serum
emulsified in complete Freund's adjuvant (1:1 v/v)
divided between 4 sites and injected s.c. on Day 0;
a similar injection was given on Day 7, followed by
an s.c. injection of 0.5ml of tumour-bearer serum
alone on Days 14 and 28. Subsequent serial test-
bleeds from the tail vein were performed on Day 31
(bleed 1), the animals boosted with 0.5ml of serum
on Day 41 and bled on Day 45 (bleed 2), reboosted
on Day 51, bled on Day 55 (bleed 3), reboosted on
Day 61 and bled on Day 65 (bleed 4) and finally all
rats were boosted on Day 71 and bled on Day 75
(bleed 5). Two hairy littermates received normal
nude rat serum using the same immunization
regime (HLM V and HLM VI). Antibodies against
normal human lymphocytes were raised in mice as
previously described (Grant & Duke, 1981); this
antiserum was used as a positive control.
Assay ofantibody binding
Antibodies in these sera binding to viable target
cells in vitro were assayed essentially as described
by Stern et al. (1978). Suspensions of viable cells
(5 x 105 cells per well in PBS) were incubated for
20min at 4°C with 50p1 of hairy littermate
antiserum (diluted 1:5) or 50p of nude rat serum
(diluted 1:5); cells were then washed (x3) in PBS
and incubated for a further 30min with 204u1 of 1251
anti-mouse Ig cross reacting with rat Ig
(-30,000cpm) after which they were washed again
and transferred to a mini-assay counter (type 6-20
Mini Instruments Ltd., Burnham on Crouch, UK).
Three assays were performed on each serum
sample; after subtraction of background using 125I
labelled second antibody alone the mean value was
expressed as cpm per 105 cells. Binding ratios were
derived by dividing the counts bound by the human
pancreatic cancer cells (GER) by the number
obtained for another cell type.
Results
All animals remained healthy throughout the study
and survived repeated general anaesthesia and tail
vein bleeding without infection or other
complication. No aFp was found in the serum of
any of the 4 pancreatic tumour bearing nude rats in
samples obtained at intervals over 180 days by
which time tumours were between 8-12cm2 in size;
serum CEA levels over the same period in 3 of
these animals were always <4ngml -1. One animal,
however, had serum CEA levels of 23ngml-1 on
Day 63 which rose progressively with tumour
growth to 166ngml-I on Day 180.
Immunological response to pancreatic tumour
xenografts
Figure 1 shows the serial dilution of tumour-
bearing nude rat serum and normal nude rat serum
assayed for antibody binding to the cell surface of
cultured GER cells using anti-mouse 1251 Ig.
Antibody binding from tumour-bearing nude rat
serum was 4 times greater than from control
normal nude rat serum suggesting the presence of
antibodies against pancreatic xenograft cell surface
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Figure 1 Antibody binding to the surface of human
pancreatic cancer cells (GER) in vitro in serial
dilutions of mu/mu nude rat sera from pancreatic
tumour bearing (- 0) and non-tumour bearing
(0 O) animals.
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Figure 2 (a and b) shows the level of circulating
anti-pancreatic-cancer cell surface antibody at
intervals over 190 days after the introduction of the
primary cancer cell implant. Tumours failed to
grow in the 3 animals (A, B, C) in Figure 2a, but
progressive tumour growth occurred as indicated in
those in Figure 2b (D, E, F). In each group
pancreatic cancer cell implantation was followed by
a rise in cell surface antibody binding. These levels
remained about the same in the 3 rats in which
tumours failed to grow (Figure 2a). In the 3 rats
showing pancreatic tumour growth (Figure 2b)
tumour progression appeared to be associated with
a rise in the level of cell surface antibody; in one
rat (D) the increase was substantial.
Immunisation of hairy littermates with xenograft
serum
Figure 3 shows the antibody response during
immunization of 4 hairy littermates (muu/+) with
pooled serum from pancreatic tumour-bearer nude
animals as well as the levels for control
immunocompetent animals immunized with normal
nude rat serum. Each rat given tumour-bearer
serum developed antibody recognising pancreatic
cancer cell surface components; this was not seen in
any of the controls. However, only one hairy
littermate immunized with tumour-bearer serum
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Figure 2 Antibody binding to the surface of human pancreatic cancer cells (GER) in vitro in serum samples
from 6 nude rats (A-F) before and up to 27 weeks after implantation of 3 x 107 GER cells on Day 0. (a) 3
rats (A, B, C) in which tumours failed to grow. (b) 3 rats (D, E, F) showing progressive tumour growth.
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Figure 3 Antibody binding to the surface of human pancreatic cancer cells (GER) in vitro in serum of
immunocompetent hairy littermates (HLM, rnu/+). HLM I-IV repeatedly immunised with serum from
human pancreatic cancer xenograft-bearing nude rats (rnu/mu); HLM V and VI repeatedly immunised with
control nude rat serum. (+s.e. 3 experiments).
(HLM III) showed a sustained rise in antibody titre
throughout the immunisation procedure. The 3
other experimental animals (HLM I, II and IV)
varied in their antibody response but all showed a
significant level of activity at 10 weeks in the range
600-800cpm per 10o GER cells compared with
190cpm per 105 GER cells in the controls.
Figure 4 shows the binding of antibody from the
immunized hairy littermate with the greatest
antibody response (HLM III) as well as antibody
from GER tumour-bearer serum, to the cell surface
of cultured human pancreatic cancer cells (GER
and WAD) using anti-mouse 1251I Ig as the second
antibody. The level of binding is compared with
that identified for a panel of other human cells
maintained in vitro.More than twice as much HLM
III antibody was bound by GER and WAD
pancreatic cancer cells than was bound by cells
from either of the human bladder cancers (TCC
and J82), the breast cancer (MDA), the
lymphoblastoid cell line (HL60) or by normal
human peripheral blood lymphocytes (HLSK). The
ratio of HLM III antibody binding by GER
compared with two human colon cancer cell lines
(CAS and HT29) was 1.7:1 in each case and by
GYL, 1.6:1. The amount of antibody from pooled
GER tumour-bearer serum binding to GER and
WAD cells was lower than with HLM III and wasXENOGENEIC ANTIBODIES TO HUMAN PANCREATIC CANCER 243
Cell line GER
10
5
U,0 0)
0.
0
L.
ul
C.,
C4
0 I
C
X
E
L.
CN
WAD TCC
ml-
J82 CAS HT29 MDA GYL HL60 HLSK
HLM IlIl antiserum
m~~~~~~~~~~~~~~~~~~~~
0.9 2.6 2.1 1.7 1.7 3.0 1.6 3.8 4.9
Binding ratio
GER tumour bearer serum
tHHfl~~~HHHH~ND
1.1 1.0 1.2 1.0 1.0 1.6 1.0 0.9
Binding ratio
Mouse anti-human lymphocyte serum
15-
10
5o
Control nude rat serum
2Fl F-rI F-lF9rr r- FI9 M Fm- 71 5
Figure 4 Binding of immunised hairy littermate (mu/+) antiserum with highest anti-GER antibody titre
(HLM III) and GER tumour-bearer nude rat antiserum, to a panel of human cells in vitro. Binding of anti-
human lymphocyte antiserum and anti-normal nude rat serum (HLM V) also shown (±s.e. of 3 experiments).
Human cell lines; GER, WAD pancreatic cancer, TCC, J82 bladder cancer; CAS and HT29 colon cancer;
MDA breast cancer; GYL kidney cancer; HL-60 lymphoblastoid; HLSK normal human lymphocytes. For
definition ofbinding ratio see text.
about the same for each of the panel of other
human cells tested.
Discussion
Serial blood sampling from athymic nude rats
following implantation of human pancreatic cancer
cells (GER) has shown that these animals develop
circulating antibodies which react with human
pancreatic cancer cells in vitro and that in general
antibody titre rises with progressive tumour growth.
In this group of animals the levels of circulating cell
surface antibody in the 6 weeks following
implantation did not appear to determine whether
tumour xenograft growth would progress
successfully or not, and the antibody response
developed despite the abnormalities of the T-cell
system (Festing et al., 1978 and Brooks et al., 1980).
Such independence of the presence of antibody is
similar to the progression of murine leukaemias
bearing TL+ antigens in TL- mice (Old, 1981). It
may be explicable on the basis of a deficiency of244 G. DAVIES et al.
complement (Vos, 1980) or the absence of a critical
population of antibody dependent cytotoxic cells; it
might also be related to an ability of tumour cells
in xenografts to modulate their display of cell
surface components.
The development of anti-GER and anti-WAD cell
surface antibody by immunocompetent rats
immunized with the serum of their GER-tumour
bearing nude relations, shows that pancreatic cancer
cell surface components are present in the
circulation of the tumour bearing nude animals
despite the presence of free circulating anti-cell
surface antibody. Such components could be in the
form of persisting immune complexes although
these animals have an apparently effective
phagocytic system which would be expected to
remove such complexes rapidly (Festing et al.,
1978). An alternative explanation is that strongly
recognised antigens are complexed and eliminated
and that the cell surface components which persist
in the circulation are predominantly those bearing
determinants which are recognised weakly or not at
all by the B-cell system of the immunodeficient host
(rnu/rnu). These more weakly recognised
components may however elicit a B-cell response by
repeated challenge of the more immunocompetent
relatives (rnu/+). Since human tumour antigens
themselves may be weak determinants (Herberman,
1977) differences in the relative immune competence
of rnu/rnu and rnu/+ rats may offer a biological
opportunity for their selective recognition prior to
hybridoma formation.
Some evidence in support of this interpretation is
provided by differences in the apparent selectivity of
antibody populations in immunized hairy littermate
and tumour-bearer nude rat sera, when tested
against the panel of other human cells. Circulating
antibody in the human pancreatic tumour bearing
nude rats (rnu/rnu) bound about equally to all the
cell types tested suggesting recognition of common
determinants. GER and WAD, however, bound
-1.5-5 times as much antibody from the sera of
the immunized hairy littermates (rnu/+) compared
with binding by the other human cancer cells and
lymphocytes tested, suggesting the formation of
antibody to pancreatic cancer associated
components. In the present study there was
insufficient HLM III antibody available to complete
absorption studies and Western blot analysis. We
cannot exclude, therefore, the possibility that
apparent selectivity in antibody binding was due to
differences in antigen density, though this was not
the case in previous studies in the mouse (Grant &
Duke, 1981).
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